Four potential lysine acetylation sites on BRD4 [289 (AC2), 291(AC1), 329 (AC3), and 332 (AC4)] were developed and expressed to examine the impact of the ISX–BRD4 complex on EMT in lung cancer cells (Fig 4A and B). This evidence concerns the gene ISX and lung carcinoma.